Clin Endosc.  2024 Nov;57(6):798-806. 10.5946/ce.2023.291.

Hepatobiliary scintigraphy of bile excretion after endoscopic ultrasound-guided hepaticogastrostomy for malignant biliary obstruction: a retrospective study in Japan

• Yamada M
• Hara K
• Haba S
• Kuwahara T
• Okuno N
• Kuraishi Y
• Yanaidani T
• Ishikawa S
• Yasuda T
• Fukui T

• KMID: 2561164
• DOI: http://doi.org/10.5946/ce.2023.291

Abstract

Background/Aims
Hepatobiliary scintigraphy (HBS) is used to evaluate bile excretion. This study aimed to evaluate biliary excretion during endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) using HBS.
Methods
We retrospectively evaluated 78 consecutive patients with malignant extrahepatic biliary obstruction, who underwent HBS after EUS-HGS between April 2015 and July 2022. The peak time and decay rate were scored with 0, 1, or 2 points based on thresholds of 20 and 35 minutes, and 10% and 50%, respectively. A total score of 4 or 3 was considered indicative of good bile excretion, whereas scores of 2, 1, or 0 indicated poor bile excretion.
Results
The good and poor bile excretion groups included 40 and 38 cases, respectively. The group with good bile excretion had a significantly longer time to recurrent biliary obstruction compared to the poor bile excretion group (not reached vs. 124 days, p=0.026). Multivariate analysis identified the site of obstruction as a significant factor influencing good bile excretion (odds ratio, 3.39; 95% confidence interval, 1.01–11.4, p=0.049), with superior bile excretion observed in cases involving upper biliary obstruction compared to middle or lower biliary obstruction.
Conclusions
In patients with malignant biliary obstruction who underwent HGS, the site of obstruction is significantly associated with stent patency.

Keyword

Endoscopic ultrasound; Endoscopic ultrasound-guided biliary drainage; Endoscopic ultrasound-guided hepaticogastrostomy; Hepatobiliary scintigraphy; Malignant biliary obstruction

Figure

• 

  Fig. 1. Study flowchart. Flowchart of 123 consecutive patients with malignant extrahepatic biliary obstruction who underwent hepatobiliary scintigraphy (HBS) within one month of undergoing hepaticogastrostomy (HGS) at Aichi Cancer Center Hospital between April 2015 and July 2022. Nine patients with separated left and right hepatic ducts due to malignant tumors, three patients who underwent HGS using plastic stents, and 33 patients who underwent HGS combined with antegrade stenting were excluded. Finally, a total of 78 consecutive patients with malignant extrahepatic biliary obstruction who underwent HBS after HGS were examined during the study period.

• 

  Fig. 2. Hepatobiliary scintigraphy. (A) The region of interest (ROI) set at the hilar bile duct. (B) Time-activity curve (TAC). The peak time and decay rate were calculated from the TAC and used as a scale to evaluate bile excretion. An example of a hepatobiliary scintigraphy is shown. The peak time and decay rate, in this case, are 10 minutes and 68.9%, respectively. (C) Key images at 5, 10, 20, and 60 minutes. At 5 minutes, the bile is excreted into the stomach via the hepaticogastrostomy (HGS) route. At 10 minutes, the accumulation in the hilar bile duct is maximal. At 20 minutes, the accumulation in the hilar bile duct is reduced, and at 60 minutes, the accumulation in the hilar bile ducts is further reduced, with most of the isotope-labeled bile excreted into the stomach. Supplemental Video 1 shows this case.

• 

  Fig. 3. Scatter plots and scoring system created based on peak time and decay rate for each case obtained from hepatobiliary scintigraphy. Scatter plots and scoring systems. From this scatter plot, the peak time and decay rate were scored as 0, 1, and 2 points based on 20 and 35 min, and 10% and 50%, respectively, and bile excretion was evaluated based on the sum of these scores. A total score of 4 or 3 was defined as good bile excretion, while scores of 2, 1, or 0 indicated poor bile excretion.

• 

  Fig. 4. Examples of biliary scintigraphy in hepaticogastrostomy (HGS) cases classified according to the scoring system. In cases with a total score of 0, isotope-labeled bile stagnates in the bile ducts and excretion from the HGS route is poor. In cases with a total score of 4, the isotope-labeled bile was not stagnant and was excreted through the HGS route early on. In cases with a total score of 2, bile excretion was intermediate, ranging from 0 to 4. Supplemental Videos 2 and 3 show the cases with total scores of 4 and 0, respectively.

• 

  Fig. 5. Comparison between the good and poor bile excretion groups concerning the time to recurrent biliary obstruction (TRBO). The TRBO of the good bile excretion group was significantly longer than that of the poor bile excretion group; the good excretion groups did not reach the median TRBO value, while the median TRBO of the poor bile excretion group was 124 days (not reached vs. 124 days, p=0.026; log-rank test).

• 

Reference

1. ASGE Standards of Practice Committee, Buxbaum JL, Abbas Fehmi SM, et al. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointest Endosc. 2019; 89:1075–1105.

2. Hayat U, Bakker C, Dirweesh A, et al. EUS-guided versus percutaneous transhepatic cholangiography biliary drainage for obstructed distal malignant biliary strictures in patients who have failed endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis. Endosc Ultrasound. 2022; 11:4–16.

3. Hassan Z, Gadour E. Percutaneous transhepatic cholangiography vs endoscopic ultrasound-guided biliary drainage: a systematic review. World J Gastroenterol. 2022; 28:3514–3523.

4. Boulay BR, Lo SK. Endoscopic ultrasound-guided biliary drainage. Gastrointest Endosc Clin N Am. 2018; 28:171–185.

5. Isayama H, Nakai Y, Itoi T, et al. Clinical practice guidelines for safe performance of endoscopic ultrasound/ultrasonography-guided biliary drainage: 2018. J Hepatobiliary Pancreat Sci. 2019; 26:249–269.

6. Ogura T, Higuchi K. Technical review of developments in endoscopic ultrasound-guided hepaticogastrostomy. Clin Endosc. 2021; 54:651–659.

7. Ogura T, Ueno S, Okuda A, et al. Expanding indications for endoscopic ultrasound-guided hepaticogastrostomy for patients with insufficient dilatation of the intrahepatic bile duct using a 22G needle combined with a novel 0.018-inch guidewire (with video). Dig Endosc. 2022; 34:222–227.

8. Okuno N, Hara K, Mizuno N, et al. B2 puncture with forward-viewing EUS simplifies EUS-guided hepaticogastrostomy (with video). Endosc Ultrasound. 2022; 11:319–324.

9. Okuno N, Hara K, Haba S, et al. Novel drill dilator facilitates endoscopic ultrasound-guided hepaticogastrostomy. Dig Endosc. 2023; 35:389–393.

10. Kato-Azuma M. TC-99m(Sn)-N-pyridoxylaminates: a new series of hepatobiliary imaging agents. J Nucl Med. 1982; 23:517–524.

11. Narabayashi I, Sugimura K, Ishido N, et al. Quantitative analysis by digital computer of 99mTc-N-pyridoxyl-5-methyltryptophan (99mTc-PMT) hepatogram in diffuse parenchymal liver diseases. Eur J Nucl Med. 1987; 13:285–287.

12. Kobayashi M, Nakanishi T, Nishi K, et al. Transport mechanisms of hepatic uptake and bile excretion in clinical hepatobiliary scintigraphy with 99mTc-N-pyridoxyl-5-methyltryptophan. Nucl Med Biol. 2014; 41:338–342.

13. Okuno N, Hara K, Mizuno N, et al. Risks of transesophageal endoscopic ultrasonography-guided biliary drainage. Gastrointest Interv. 2017; 6:82–84.

14. Isayama H, Hamada T, Yasuda I, et al. TOKYO criteria 2014 for transpapillary biliary stenting. Dig Endosc. 2015; 27:259–264.

15. Yokoe M, Hata J, Takada T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci. 2018; 25:41–54.

16. Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010; 71:446–454.